Retirees tend to love stocks that combine big dividends, inflation-beating dividend growth, strong balance sheets, and durable and defensive business models. Even better, when retirees can buy these sorts of stocks at clear discounts to intrinsic value, they also can enjoy big upside potential. We share two of the best opportunities that check these boxes right now.

KBE offers highly diversified, best-in-class exposure to regional and diversified banks, with a competitive expense ratio and solid dividend yield. The fund trades at a significant valuation discount to the S&P 500 and the broader financial sector, providing some downside cushion. Upcoming rate cuts and weak loan demand pose risks to margins, especially for regional banks more exposed to economic softness and consumer weakness.

IMO offers robust returns, record production and growth prospects, but dependence on Exxon, weak chemicals and commodity swings can weigh on the stock.

Nvidia (NASDAQ:NVDA) stock continues to be the talk of the town.

PHILADELPHIA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against KinderCare Learning Companies, Inc. (NYSE: KLC) (“KinderCare” or the “Company”) on behalf of investors who purchased or acquired shares during the period from October 6, 2024 through August 12, 2025 (the “Class Period”), including in or traceable to the Company's October 2024 initial public offering (“IPO”).

EXEL rides on Cabometyx growth and zanzalintinib's trial success, but Q2 revenue miss and competition keep investor sentiment cautious.

Hasbro (HAS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Evaluate the expected performance of Amer Sports, Inc. (AS) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Intercorp Financial Services (IFS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Oncobiologics, Inc. (OTLK) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.83 per share a year ago.

Clene Inc. (CLNN) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to a loss of $1.06 per share a year ago.

Evaluate the expected performance of Home Depot (HD) for the quarter ended July 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Douglas Dynamics (PLOW) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

VYNE Therapeutics Inc. (VYNE) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.22 per share a year ago.

Beyond analysts' top-and-bottom-line estimates for Medtronic (MDT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended July 2025.

Evaluate the expected performance of Premier (PINC) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Besides Wall Street's top-and-bottom-line estimates for Jack Henry (JKHY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.

Get a deeper insight into the potential performance of Alcon (ALC) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Get a deeper insight into the potential performance of Toll Brothers (TOL) for the quarter ended July 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Evaluate the expected performance of Keysight (KEYS) for the quarter ended July 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.